AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA
1 day ago · THOUSAND OAKS, Calif., Nov. 13, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data. "As ...
The Maritime Executive: Maritime News | Marine News
The maritime industry’s leading source for breaking maritime and marine news including shipping news, offshore news, piracy news and more
AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA
1 day ago · Published. Nov 13, 2024 5:00am EST. THOUSAND OAKS, Calif., Nov. 13, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly ...
Amgen Defends Its Investigational Monthly Weight Loss Injection …
1 day ago · On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug. On Wednesday, Amgen Inc ...
gCaptain – Maritime News
Discover the latest maritime news, shipping updates, and offshore industry insights at gCaptain. Trusted by mariners and shipping professionals worldwide, gCaptain delivers real-time reports ...
USNI News - Maritime News and Analysis
2 days ago · Every week, USNI News highlights U.S. Navy, Marine and Coast Guard operations around the world. Aviation News on the latest developments in U.S. and international aviation.
Seatrade Maritime News | Global Maritime & Shipping News …
1 day ago · Daily maritime news covering marine, shipping and offshore updates from the global maritime industry. Sign-up for the daily maritime newsletter.
Amgen obesity drug MariTide: four key questions going ... - STAT
May 3, 2024 · The injectable drug MariTide, designed to be given monthly, could be a more attractive option than Wegovy and Zepbound, which are both dosed weekly.
Amgen goes all in on injectable obesity treatment MariTide - STAT
May 2, 2024 · The injectable drug, called MariTide, is in a Phase 2 trial for obesity, and Chief Executive Bob Bradway said on an earnings call that “we are very encouraged with the results” from an interim ...
Amgen Suffers Surprise Blow as New Bone Density Safety
1 day ago · Amgen lost more than 7% of its value in trading on Tuesday after reports circulated that its highly anticipated obesity candidate MariTide could have negative effects on bone mineral density, raising concerns that the investigational therapy could aggravate the risk of fractures in patients. The bone marrow density (BMD) data were first spotted ...